Bristol-Myers Squibb Co. announced on Thursday that it has changed the labeling for Tequin (gatifloxacin), an antibiotic used to treat pneumonia, bronchitis, uncomplicated gonorrhea, and infections such as urinary tract, kidneys, and skin.
The U.S. Food and Drug Administration (FDA) says the labeling changes update the prescription information as a result of continued reports of serious cases of hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) in patients receiving Tequin
